2023 World Conference on Lung Cancer (Posters)-EP14.01. Clinical Significance of BAP1 Expression in Malignant Mesothelioma Treated with Ipilimumab and Nivolumab.

EP14.01. Clinical Significance of BAP1 Expression in Malignant Mesothelioma Treated with Ipilimumab and Nivolumab. - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to analyze the efficacy and predictive biomarkers of combination therapy with ipilimumab (IPI) and nivolumab (NIVO) in patients with unresectable or metastatic malignant pleural mesothelioma (MPM). The study included 29 patients who received NIVO and IPI, with 18 patients treated as second-line therapy and 11 patients treated as third-line or later therapy. The histological subtypes of the patients included epithelial, biphasic, and sarcoma types. The overall response rate was 32%, with three patients achieving a complete response and five patients achieving a partial response. The median progression-free survival (PFS) was 2.5 months. BAP1 expression was evaluated in 14 patients, and seven of them lost BAP1 nuclear expression. Patients with BAP1 loss had significantly longer PFS compared to BAP1 intact or unknown patients. The study suggests that ipilimumab and nivolumab combination therapy is a well-tolerated treatment option for MPM patients with BAP1 loss. Further studies are needed to validate these results. Additionally, ongoing predictive biomarker studies of immunotherapy in MPM are being conducted. BAP1 is a tumor suppressor gene that regulates gene expression and is commonly mutated in MPM. The study retrospectively analyzed the impact of BAP1 alteration on the clinical outcome of NIVO and IPI therapy in previously treated MPM. A clinical case was presented that showcased a dramatic and long-term response to NIVO/IPI treatment.

Asset Subtitle

Sook-hee Hong

Meta Tag

Speaker Sook-hee Hong

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

combination therapy

ipilimumab

nivolumab

malignant pleural mesothelioma

BAP1 expression

BAP1 loss

progression-free survival

treatment option

immunotherapy

clinical outcome